Developing national capability for the production and use of radiometal based radiopharmaceuticals

Simple item page
dc.contributor.authorLengkeek, NAen_AU
dc.contributor.authorPellegrini, PAen_AU
dc.contributor.authorOehlke, Een_AU
dc.contributor.authorFraser, BHen_AU
dc.contributor.authorGreguric, Ien_AU
dc.date.accessioned2021-08-11T04:46:14Zen_AU
dc.date.available2021-08-11T04:46:14Zen_AU
dc.date.issued2013-04-11en_AU
dc.date.statistics2021-08-10en_AU
dc.descriptionOpen Accessen_AU
dc.description.abstractRadiometals remain key radioisotopes for radio-medicine; the mainstay diagnostic medical imaging isotope, 99mTc, and important radioisotopes for radiotherapy, 90Y and 153Sm. However, the worldwide growth in PET centres, driven by the wildly successful [18F]-FDG, has provided a yet to be seized opportunity to deliver radiometal-based radiopharmaceuticals with clinical relevance to researchers. An ever growing set of radiometals is becoming available in Australia covering a wide range of half-lives, nuclear and chemical properties, these include 64Cu, 68Ga, 86Y, 89Zr, and looking into the near future, 44Sc, 45Ti and 90Nb. ANSTO's Lifesciences division is working to provide the Australian academic and clinical communities access to the following key areas. Radioisotope supply Two in-house 68Ge/68Ga generators; one solely for research and a larger generator for pre-clinical trials, provide access to this key radioisotope. ANSTO has provided financial and technical support to numerous cyclotron centres around Australia for development of solid targetry facilities, ensuring supply of 124I, 64Cu, 86Y and 89Zr in the short-term and 44Sc, 45Ti and 90Nb later. In coming years the OPAL reactor will begin producing pharmaceutical grade 177Lu as part of the Australian government's investment in nuclear medicine. Radiometal Labelling Research and Development In addition to our programs developing new ligands, tracers and improved radiometal labelling procedures, Lifesciences is supporting the development of new biomolecule treatments by providing researchers access to laboratories, procedures and expertise tailored specifically for functionalising biomolecules for radiometal labelling. Preclinical Radiometal Tracer Development We are working to deliver novel radiometal-based diagnostic tracers to the Australian research and clinical community by accessing the pre-clinical programs of our key international partnerships at Memorial Sloan Kettering Cancer Centre and Massachusetts General Hospital. Our initial objective is to supply the antibodies, i.e. [ 89 Zr]-J591. As our supply radiometals is diversified we will expand into proteins, peptides and other biomolecules. © 2013 John Wiley & Sons, Inc.en_AU
dc.identifier.citationLengkeek, N., Pellegrini, P., Oehlke, E., Fraer, B., & Greguric, I. (2013). Developing national capability for the production and use of radiometal based radiopharmaceuticals. Poster presented at the 43rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), 11-15 April, 2013, Perth Convention and Exhibition Centre, Perth Australia. In Internal Medicine Journal, 43 (S1), 22. doi:10.1111/imj.12133en_AU
dc.identifier.conferenceenddate15 September 2013en_AU
dc.identifier.conferencename43rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM)en_AU
dc.identifier.conferenceplacePerth, Australiaen_AU
dc.identifier.conferencestartdate11 September 2013en_AU
dc.identifier.issn1445-5994en_AU
dc.identifier.issueS1en_AU
dc.identifier.journaltitleInternal Medicine Journalen_AU
dc.identifier.pagination22en_AU
dc.identifier.urihttps://doi.org/10.1111/imj.12133en_AU
dc.identifier.urihttps://apo.ansto.gov.au/dspace/handle/10238/11322en_AU
dc.identifier.volume43en_AU
dc.language.isoenen_AU
dc.publisherJohn Wiley & Sons, Incen_AU
dc.subjectPositron computed tomographyen_AU
dc.subjectAustraliaen_AU
dc.subjectANSTOen_AU
dc.subjectRadiopharmaceuticalsen_AU
dc.subjectRadioisotopesen_AU
dc.subjectOPAL Reactoren_AU
dc.subjectNuclear medicineen_AU
dc.subjectLabellingen_AU
dc.subjectTracer techniquesen_AU
dc.titleDeveloping national capability for the production and use of radiometal based radiopharmaceuticalsen_AU
dc.typeConference Posteren_AU
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
imj.12133.pdf
Size:
1.09 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Conference Publications